Rahway, NJ., June 12, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for the NOBIVAC® L6 and NOBIVAC® LoVo L6 vaccines. If the European Commission (EC) adopts the recommendation, the […]
If Approved, NUMELVI Will Be the First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Treatment of Pruritus Associated with Allergic Dermatitis Including Atopic Dermatitis and Treatment of Clinical Manifestations of Atopic Dermatitis in Dogs RAHWAY, N.J., June 12, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA […]
RAHWAY, NJ, May 16, 2025 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) issued a positive opinion for the INNOVAX®-ND-IBD-ILT vaccine. If approved, this will be the only single-dose vaccine approved in the EU to […]
If approved by the European Commission, the vaccine will become an available tool for governments to consider as part of a holistic strategy to combat the spread of highly pathogenic avian influenza (HPAI) which may include additional vaccinations plus enhanced biosecurity and surveillance Potentially the first centrally registered vaccine in the European Union against the […]